Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,663,159

« Back to Dashboard

Summary for Patent: 5,663,159

Title: Prodrugs of phosphonates
Abstract:There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.
Inventor(s): Starrett, Jr.; John E. (Middletown, CT), Mansuri; Muzammil M. (Cheshire, CT), Martin; John C. (Cheshire, CT), Tortolani; David R. (Meriden, CT), Bronson; Joanne J. (Madison, CT)
Assignee: Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) N/A (BE) Rega Stichting v.z.w. (
Application Number:08/320,632
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

International Patent Family for Patent: 5,663,159

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2051239► Subscribe
Germany10399025► Subscribe
Germany69129650► Subscribe
Denmark0481214► Subscribe
European Patent Office0481214► Subscribe91036Luxembourg► Subscribe
European Patent Office0481214► Subscribe300131Netherlands► Subscribe
European Patent Office0481214► SubscribeSPC/GB03/030United Kingdom► Subscribe
European Patent Office0481214► SubscribeC300131Netherlands► Subscribe
European Patent Office0481214► Subscribe03C0034France► Subscribe
Brazil1100467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: